

27. The immune adjuvant composition as claimed in claim 19, wherein the immunostimulatory oligonucleotide comprises a CpG motif having the formula 5'X1CGX23', wherein X1 is adenine, guanine, or thymine, and X2 is cytosine, thymine, or adenine.

28. The immune adjuvant composition as claimed in claim 27, wherein the CpG motif comprises TCTCCCAGCGTGCGCCAT (SEQ ID NO:1).

54. The method as claimed in claim 49, wherein the immunostimulatory oligonucleotide comprises a CpG motif comprising more than one unmethylated CpG dinucleotide.

58. The method as claimed in claim 57, wherein the CpG motif comprises TCTCCCAGCGTGCGCCAT (SEQ ID NO:1).

59. The method as claimed in claim 49, wherein the individual is a mammal.

60. The method as claimed in claim 49, wherein the individual is a human.

61. The method as claimed in claim 49, wherein the individual is an animal.

63. An immune adjuvant composition comprising
a. a saponin adjuvant; and
b. an immunostimulatory oligonucleotide comprising at least one CpG motif,
wherein the saponin adjuvant comprises substantially pure QS-7, QS-17 or QS-18.

65. An immune adjuvant composition comprising
a. a saponin adjuvant; and
b. an immunostimulatory oligonucleotide comprising at least one CpG motif,
wherein the immunostimulatory oligonucleotide is modified.

69. An immune adjuvant composition comprising
a. a saponin adjuvant; and

09
b. an immunostimulatory oligonucleotide comprising at least one unmethylated CpG motif,
wherein the immunostimulatory oligonucleotide comprises TCTCCCAGCGTGCGCCAT (SEQ ID NO:1).

1010
71. An immune adjuvant composition comprising
a. a saponin adjuvant; and
b. an immunostimulatory oligonucleotide comprising at least one unmethylated CpG motif,
wherein the immunostimulatory oligonucleotide comprises TCCATGACGTTCTGACGTT (SEQ ID NO:2).

Sub e4
D11
73. An immune adjuvant composition comprising
a. a saponin adjuvant; and
b. an immunostimulatory oligonucleotide, wherein said immunostimulatory oligonucleotide is from 4-40 base pairs in length, comprising at least one unmethylated CpG motif.

Sub e4
D12
75. An immune adjuvant composition comprising
a. a saponin adjuvant; and
b. an immunostimulatory oligonucleotide comprising at least one unmethylated CpG motif;
wherein the saponin adjuvant is a chemically modified saponin adjuvant.

D13
78. The immune adjuvant composition as claimed in claim 27, wherein the CpG motif comprises TCCATGACGTTCTGACGTT (SEQ ID NO:2).

79. The method as claimed in claim 57, wherein the CpG motif comprises TCCATGACGTTCTGACGTT (SEQ ID NO:2).

Sub e5
D14
80. (new) The immune adjuvant composition as claimed in claim 19, wherein the composition increases the immune response to an antigen when administered to an individual.

81. (new) The immune adjuvant composition as claimed in claim 80, wherein the individual is a mammal.

82. (new) The immune adjuvant composition as claimed in claim 80, wherein the individual is a human.

83. (new) The immune adjuvant composition as claimed in claim 80, wherein the individual is an animal.

84. (new) The immune adjuvant composition as claimed in claim 19, further comprising an antigen selected from the group consisting of a protein, a peptide, a polysaccharide, a lipid, and a nucleic acid encoding the protein or peptide.

85. (new) The immune adjuvant composition as claimed in claim 84, wherein the antigen is a lipid.

86. (new) The immune adjuvant composition as claimed in claim 85, wherein the lipid is a glycolipid or a phospholipid.

87. (new) The method as claimed in claim 59, wherein the antigen comprises a protein, a peptide, a polysaccharide, a lipid, or a nucleic acid encoding the protein or peptide.

88. (new) The method as claimed in claim 87, wherein the antigen is a lipid.

89. (new) The method as claimed in claim 88, wherein the lipid is a glycolipid or a phospholipid.

REMARKS

Claims 1-18, 29-48, and 62 have been canceled without prejudice.

Applicant reserves the right to prosecute the subject matter of any canceled claim in one or more continuation, continuation-in-part, or divisional applications. Claims 19-32 and 49-83 are pending. Claims 19, 24, 27, 28, 54, 58-61, 63, 65, 69, 71, 73, 75, 78-79 have been amended to more particularly point out and distinctly claim the invention; to place the